Provention Bio (PRVB) announced it has cancelled the release of its fourth quarter and full year financial results for the period ended December 31, 2022 due to the announcement earlier today that Provention has entered into a definitive agreement to be acquired by Sanofi (SNY), Provention’s U.S. TZIELD co-promotion partner, subject to customary regulatory and other closing conditions. In addition, Provention will no longer hold its fourth quarter and full year results conference call that had been scheduled for 8:00 am E.T. Thursday, March 16, 2023. However, Provention will file its annual report on Form 10-K in compliance with the applicable Securities Exchange Commission deadline of March 31, 2023..
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PRVB:
- Provention Bio Soars after Acquisition by Sanofi for $2.9 Billion
- Sanofi acquires Provention Bio for $25 per share or $2.9B
- Provention Bio management to meet virtually with Oppenheimer
- Provention Bio price target lowered to $16 from $18 at H.C. Wainwright
- Provention Bio management to meet with Oppenheimer
